Insulinoma differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
| Line 20: | Line 20: | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! rowspan="2" |Diseases | ! rowspan="2" |Diseases | ||
! colspan=" | ! colspan="8" |Laboratory Findings differentiating among causes of Hypoglycemia | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
!S.Glucose<br>(mg/dL)/(mmol/L) | !S.Glucose<br>(mg/dL)/(mmol/L) | ||
| Line 28: | Line 28: | ||
!S. Beta hydroxybutyrate | !S. Beta hydroxybutyrate | ||
!Glucose increase after glucagon(mg/dL) | !Glucose increase after glucagon(mg/dL) | ||
!S. Oral Hypoglycemic agent | |||
!Antibodies to Insulin | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Exogenous Insulin | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Exogenous Insulin | ||
| Line 37: | Line 39: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Insulinoma]]/[[Nesidioblastosis]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Insulinoma]]/[[Nesidioblastosis]]/PGPH† | ||
| style="background: #F5F5F5; padding: 5px;" |' | | style="background: #F5F5F5; padding: 5px;" |' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 69: | Line 71: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|} | |} | ||
† PGPH= Post Gastric Bypass Hypoglycemia | |||
==References== | ==References== | ||
Revision as of 15:33, 28 August 2017
|
Insulinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Insulinoma differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Insulinoma differential diagnosis |
|
Risk calculators and risk factors for Insulinoma differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]
Overview
Insulinoma must be differentiated from other diseases that cause features of hypoglycemia like palpitations, profuse sweating, dizziness, such as [differential dx1], [differential dx2], and [differential dx3].
OR
Insulinoma must be differentiated from the exogenous use of insulin, drugs causing hypoglycemia like sulfonylureas.
Differentiating insulinoma from other Diseases
- [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
- [Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].
- As [disease name] manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other diseases that cause [clinical feature 2], such as [differential dx3] and [differential dx4].
Preferred Table for differentials for Hypoglycemia
| Diseases | Laboratory Findings differentiating among causes of Hypoglycemia | |||||||
|---|---|---|---|---|---|---|---|---|
| S.Glucose (mg/dL)/(mmol/L) |
C Peptide (pmol/L) | S.Insulin (μU/mL)/(pmol/L) | S.Proinsulin (pmol/L) |
S. Beta hydroxybutyrate | Glucose increase after glucagon(mg/dL) | S. Oral Hypoglycemic agent | Antibodies to Insulin | |
| Exogenous Insulin | <50/2.5 | <200 | ↑↑ | |||||
| Insulinoma/Nesidioblastosis/PGPH† | ' | ↑ | - | |||||
| Autoimmune Insulin | ↓ | |||||||
| Differential Diagnosis 4 | ||||||||
| Differential Diagnosis 5 | ||||||||
† PGPH= Post Gastric Bypass Hypoglycemia